Navigation Links
Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference
Date:11/19/2008

PALO ALTO, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced that it has cancelled its corporate presentation planned for today at the Lazard Capital Markets 5th Annual Healthcare Conference due to the proximity of the release of preliminary top-line data from the first Phase III pivotal clinical trial of JZP-6 (sodium oxybate) for the treatment of fibromyalgia.

The company anticipates that it will release the preliminary top-line data within the next week.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit http://www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains a forward-looking statement related to the timing of the release of clinical results related to Jazz Pharmaceuticals' JZP-6 product candidate for the treatment of fibromyalgia. This forward-looking statement is based on the company's current expectations and inherently involves significant risks and uncertainties. The actual timing of the release of clinical results could differ from that anticipated in such forward-looking statement as a result of these risks and uncertainties. Risk factors related to Jazz Pharmaceuticals' clinical trials are discussed under "Risk Factors" in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 14, 2008.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MiddleBrook Pharmaceuticals Hires Key Commercial Team Members
2. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
3. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
4. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
5. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
6. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
7. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
8. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
9. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
10. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
11. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... TURIN, Italy , April 29, 2016 ... version 5.11, the latest update to its industry-leading treatment ... has shown that Monaco version ... Users can now attain calculation speeds up to four ... Monaco . With the industry,s gold standard ...
(Date:4/28/2016)... 2016 Q BioMed Inc. ... CEO  was featured in an article he wrote ... Fear To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... is an essential business journal for life science ... to Big Pharmas. Their content is designed to ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... will deliver a talk on its first-in-class technologies for tissue stem cell ... Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, ...
(Date:4/28/2016)... ... 28, 2016 , ... Morris Midwest ( http://www.morrismidwest.com ), a ... at its Maple Grove, Minnesota technical center, May 11-12. The event will ... Almost 20 leading suppliers of tooling, accessories, software and other related technology will ...
Breaking Biology Technology:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
Breaking Biology News(10 mins):